AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35223458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20)
Number of subjects: 67
Study 35223458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with anastrozole (Part B, n=16)
Number of subjects: 67
Study 35223458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with tamoxifen (Part C, n=16)
Number of subjects: 67
Study 35223458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with exemestane (Part D, n=15)
Number of subjects: 67
Study 35223882 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Number of subjects: 86
Study 35223882 — intervention group
Group type: COMPARATOR
Intervention: Delayed photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Number of subjects: 86
Study 35223882 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PDT with IVC
Number of subjects: 86
Study 35223882 — intervention group
Group type: COMPARATOR
Intervention: Delayed PDT with IVC
Number of subjects: 86
Study 35224534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of linguistic and acoustic features in semi-structured conversations
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: Any admission in the preceding 2 months
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit at ED arrival ≤ 35%
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing cardiovascular disease (valvular disease or myocardial infarction)
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMV at discharge
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: No appointment with a specialist after discharge
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported need for help at home
Number of subjects: 0
Study 35224712 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol EQ-5D score before the admission
Number of subjects: 0
Study 35224732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin with or without prednisone
Number of subjects: 560
Study 35224732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin with prednisone
Number of subjects: 560
Study 35224732 — intervention group
Group type: COMPARATOR
Intervention: MMF compared with prednisone
Number of subjects: 560
Study 35224732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 560
Study 35224732 — intervention group
Group type: COMPARATOR
Intervention: Other interventions (e.g., monoclonal antibodies, rituximab, dexamethasone)
Number of subjects: 560
Study 35224730 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents
Number of subjects: 51959
Study 35225085 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 54
Study 35225821 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent SMART + TAU
Number of subjects: 440
Study 35225821 — intervention group
Group type: COMPARATOR
Intervention: Residential TAU only
Number of subjects: 440
Study 35226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment for advanced HCC
Number of subjects: 542
Study 35226112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subgroup (score = 3+)
Number of subjects: 542
Study 35226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk subgroup (score = 2)
Number of subjects: 542
Study 35226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk subgroup (score = 0-1)
Number of subjects: 542
Study 35226304 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with fluvoxamine or fluconazole
Number of subjects: 0
Study 35226304 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with strong CYP2C19 inhibitors
Number of subjects: 0
Study 35226304 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with strong CYP2C19/2C9 inducers
Number of subjects: 0
Study 35226304 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with OAT3 inhibitors
Number of subjects: 0
Study 35226559 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 0
Study 35226732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Stand Test (CST) cutoff of 14 seconds for ages 70-79
Number of subjects: 1595
Study 35226732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Stand Test (CST) cutoff of 16 seconds for ages 80+
Number of subjects: 1595
Study 35226739 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat)
Number of subjects: 0
Study 35226739 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat) + rituximab
Number of subjects: 0
Study 35226739 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat) + daratumumab
Number of subjects: 0
Study 35226945 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE)
Number of subjects: 170
Study 35226999 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal stress levels (measured by PHQ-D)
Number of subjects: 277
Study 35226999 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cortisol levels during pregnancy
Number of subjects: 277
Study 35226999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI
Number of subjects: 277
Study 35227201 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings (Ground glass opacity, consolidation, pleural effusion)
Number of subjects: 380
Study 35227201 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings (Cluster with low prevalence of GGO and high prevalence of pleural effusion)
Number of subjects: 380
Study 35227201 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings (Pleural effusion)
Number of subjects: 380
Study 35227313 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/S-amlodipine 2.5 mg
Number of subjects: 316
Study 35227313 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 316
Study 35228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of PEEP
Number of subjects: 0
Study 35229612 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulant (DOAC) use in patients with MHCs
Number of subjects: 67503
Study 35229612 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without MHCs)
Number of subjects: 67503
Study 35229652 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy with increased frequency
Number of subjects: 0
Study 35229827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated proton radiation therapy (FPRT) to a total dose of 50.4 to 54 Gy RBE over 28 to 30 fractions
Number of subjects: 20
Study 35229827 — intervention group
Group type: EXPERIMENTAL
Intervention: FPRT
Number of subjects: 20
Study 35230138 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
Number of subjects: 0
Study 35230142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Number of subjects: 0
Study 35230165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription opioid use in women living with HIV
Number of subjects: 0
Study 35230165 — intervention group
Group type: COMPARATOR
Intervention: Prescription opioid use in women without HIV
Number of subjects: 0
Study 35230183 — intervention group
Group type: EXPERIMENTAL
Intervention: TIC assessment of dynamic contrast-enhanced MRI scans
Number of subjects: 244
Study 35230183 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of dynamic contrast-enhanced MRI scans
Number of subjects: 244
Study 35230185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI features including late gadolinium enhancement (LGE), T1 and T2 mapping, and extracellular volume fraction (ECV)
Number of subjects: 0
Study 35230209 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported executive functions (EFs)
Number of subjects: 40
Study 35230209 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective executive functions (EFs)
Number of subjects: 40
Study 35230209 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessment
Number of subjects: 40
Study 35230209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interventions targeting EFs
Number of subjects: 40
Study 35230209 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 35230243 — intervention group
Group type: EXPERIMENTAL
Intervention: PedAMINES app (mobile app)
Number of subjects: 278
Study 35230254 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with antihypertensive treatment titration
Number of subjects: 0
Study 35230254 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35230489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared fluorescence imaging (NIR-FI) with indocyanine green (ICG)
Number of subjects: 66
Study 35230699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 769
Study 35230699 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone and prednisolone
Number of subjects: 769
Study 35230699 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNIs) with reduced-dose prednisolone or without prednisolone
Number of subjects: 769
Study 35230699 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with reduced-dose prednisolone
Number of subjects: 769
Study 35230699 — intervention group
Group type: COMPARATOR
Intervention: Levamisole and prednisolone
Number of subjects: 769
Study 35230974 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting collagens that signal through LAIR-1 in combination with blockade of TGF-β and PD-L1
Number of subjects: 0
Study 35230981 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS)
Number of subjects: 13
Study 35230981 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 13
Study 35231008 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 55
Study 35231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SMI
Number of subjects: 1258
Study 35231037 — intervention group
Group type: COMPARATOR
Intervention: Blood donors (control group)
Number of subjects: 1258
Study 35232410 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y radioembolization
Number of subjects: 170
Study 35232419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 Receptor antagonist (IL-1Ra) measured in serum levels during 6 months follow-up.
Number of subjects: 242
Study 35232419 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery-Asberg Depression Rating Scale (MADRS) score, Alcohol Use Disorders Identification Test (AUDIT) score, Body Mass Index (BMI) assessments.
Number of subjects: 242
Study 35232419 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 242
Study 35232680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous- or intravesical-administered immune checkpoint inhibitors
Number of subjects: 13
Study 35232680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab as monotherapy
Number of subjects: 13
Study 35232680 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor response
Number of subjects: 13
Study 35232680 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response rate
Number of subjects: 13
Study 35232756 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 285
Study 35234178 — intervention group
Group type: EXPERIMENTAL
Intervention: eLASV (estimated levator ani subtended volume)
Number of subjects: 51
Study 35234654 — intervention group
Group type: EXPERIMENTAL
Intervention: eDOL mHealth app
Number of subjects: 105
Study 35234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring intervention using composite web-based multidimensional PA feedback with real-time daily feedback
Number of subjects: 51
Study 35234658 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 51
Study 35234659 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch Series 6
Number of subjects: 150
Study 35234659 — intervention group
Group type: COMPARATOR
Intervention: Withings Move
Number of subjects: 150
Study 35234659 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch ECG and pulse oximeter features
Number of subjects: 150
Study 35234659 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient and outpatient healthcare utilisation
Number of subjects: 150
Study 35234665 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive closed-loop ECoG decoder for bimanual control of an exoskeleton
Number of subjects: 0
Study 35234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous gentamicin (7.5 mg/kg daily for 14 days)
Number of subjects: 5
Study 35234826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous gentamicin (10 mg/kg daily for 24 days)
Number of subjects: 5
Study 35234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin treatment
Number of subjects: 5
Study 35234887 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP Group Lifestyle Balance (GLB) program delivered via face-to-face groups or DVD with weekly telephonic coach contact
Number of subjects: 99
Study 35234975 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured Achilles tendon
Number of subjects: 37
Study 35234975 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured leg
Number of subjects: 37
Study 35235003 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures (recurrent)
Number of subjects: 200
Study 35235003 — intervention group
Group type: COMPARATOR
Intervention: Seizures (single)
Number of subjects: 200
Study 35235003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidosis at seizure onset
Number of subjects: 200
Study 35235003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior emergency operations
Number of subjects: 200
Study 35235003 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy
Number of subjects: 200
Study 35235061 — intervention group
Group type: EXPERIMENTAL
Intervention: DVP + Li
Number of subjects: 75
Study 35235061 — intervention group
Group type: EXPERIMENTAL
Intervention: DVP + QTP
Number of subjects: 75
Study 35235061 — intervention group
Group type: COMPARATOR
Intervention: DVP + PBO
Number of subjects: 75
Study 35235189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (first-line)
Number of subjects: 1348
Study 35235189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (second-line or later)
Number of subjects: 1348
Study 35235189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 1348
Study 35235414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibition as Single Therapy
Number of subjects: 0
Study 35235412 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors plus endocrine therapy
Number of subjects: 217
Study 35235412 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 217
Study 35235572 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines during the first trimester
Number of subjects: 3094227
Study 35235572 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines <1 mg/day
Number of subjects: 3094227
Study 35235572 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines >2.5 mg/day
Number of subjects: 3094227
Study 35235572 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific benzodiazepine agents
Number of subjects: 3094227
Study 35235572 — intervention group
Group type: COMPARATOR
Intervention: Unexposed pregnancies
Number of subjects: 3094227
Study 35235641 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of hyperinsulinemia derived from OGTT (area under the curve of insulin, peak insulin, fasting insulin, insulinogenic index, insulin at 30 min)
Number of subjects: 591
Study 35235641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postprandial glucose <75 mg/dL
Number of subjects: 591
Study 35235641 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up >4 years in a subsample of 104 participants
Number of subjects: 591
Study 35235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 493
Study 35235656 — intervention group
Group type: COMPARATOR
Intervention: Continuing current antiretroviral regimens (CAR)
Number of subjects: 493
Study 35235725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurements obtained 3 to 12 hours after surgery and on days 1, 2, and 3 after surgery.
Number of subjects: 13862
Study 35235733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0
Study 35235733 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35235940 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-3RP intervention
Number of subjects: 80
Study 35236170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding
Number of subjects: 4470
Study 35236170 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 4470
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy aging (HA)
Number of subjects: 2157
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2157
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2157
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 2157
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster gait speed
Number of subjects: 2157
Study 35236290 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster performance in sit-to-stand test
Number of subjects: 2157
Study 35236302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) for 8 weeks (1500-3000 mg total daily dose)
Number of subjects: 166
Study 35236302 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC) for 8 weeks (1500-6500 mg total daily dose) followed by LC for 8 weeks (1500-3000 mg total daily dose)
Number of subjects: 166
Study 35236302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) for up to 6 months (1500-3000 mg total daily dose)
Number of subjects: 166
Study 35236331 — intervention group
Group type: COMPARATOR
Intervention: obinutuzumab (G)-CHOP
Number of subjects: 509
Study 35236331 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax+[G/R]-CHOP
Number of subjects: 509
Study 35236331 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2/EZH2
Number of subjects: 509
Study 35236331 — intervention group
Group type: EXPERIMENTAL
Intervention: MYD88/CD79B
Number of subjects: 509
Study 35236342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (VDD)
Number of subjects: 0
Study 35236342 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke (CS) exposure
Number of subjects: 0
Study 35236342 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 supplementation in COPD patients
Number of subjects: 0
Study 35236373 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith, Activity, and Nutrition (FAN) program intervention
Number of subjects: 92
Study 35236375 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MaZiRenWan (MZRW)
Number of subjects: 60
Study 35236375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35236419 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (confident, active, and happy youth)
Number of subjects: 20
Study 35236510 — intervention group
Group type: EXPERIMENTAL
Intervention: SurgeCon quality improvement intervention
Number of subjects: 4
Study 35236551 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS)
Number of subjects: 1963
Study 35237053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-7 days
Number of subjects: 302
Study 35237053 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g every 24 h for 5-7 days
Number of subjects: 302
Study 35237316 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux mucosectomy
Number of subjects: 13
Study 35237394 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc individualized prophylaxis
Number of subjects: 0
Study 35237650 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 18
Study 35237699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial root repair for medial and lateral posterior meniscal root tears
Number of subjects: 45
Study 35237699 — intervention group
Group type: COMPARATOR
Intervention: Age ≥ 50 years
Number of subjects: 45
Study 35237699 — intervention group
Group type: COMPARATOR
Intervention: Increased BMI, cartilage status, and meniscal extrusion
Number of subjects: 45
Study 35237748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 600 mg twice daily for five days
Number of subjects: 1092
Study 35237748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study 35237748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 1092
Study 35238436 — intervention group
Group type: EXPERIMENTAL
Intervention: First COVID-19 lockdown
Number of subjects: 239
Study 35238467 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy recommended by the Molecular Tumor Board (MTB)
Number of subjects: 51
Study 35238467 — intervention group
Group type: COMPARATOR
Intervention: Unmatched therapy
Number of subjects: 51
Study 35238615 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture during chemotherapy infusion
Number of subjects: 0
Study 35238615 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35238785 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI seeking
Number of subjects: 76
Study 35238785 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 76